Daratumumab,Talquetamab,Teclistamab,Pomalidomide
Genmab,Janssen
['mmsm']
aa3/ oral/skin and nail aes mostly were g1/2: 70-90%! 17% required dose reduction while only 1.5% discontinued due to aes. 77% had dysgeusia #mmsm #myeloma #medtwitter #meded #asco23 #usmirc 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter